Sernova gets under the skin
The company believes its new combination technology can make insulin injections a thing of the past.
The next generation of diabetes technology
New devices are coming, but the real advances will involve combinations.
Go or no go? Lilly’s valuable diabetes contender
Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.
Lilly takes on Novo in obesity
Tirzepatide is coming for Wegovy’s crown – and maybe faster than expected.
Embecta seeks high growth with low tech
The diabetes-focused Becton Dickinson spinoff intends to spend – but can it compete in insulin pumps?
Big pharma’s key second-quarter data
Roche awaits Tigit and Serd data, Lilly takes on obesity, and Glaxo and Pfizer race in RSV.
